{"id":"hc-1119","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-15%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Vomiting"}]},"_chembl":{"chemblId":"CHEMBL4594421","moleculeType":"Small molecule","molecularWeight":"467.46"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting the SGLT2 receptor, HC-1119 reduces glucose reabsorption in the kidneys, leading to a decrease in blood glucose levels. This mechanism is particularly useful in the treatment of type 2 diabetes.","oneSentence":"HC-1119 is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:14:51.715Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT03851640","phase":"PHASE3","title":"A Trial Evaluating the Efficacy and Safety of HC-1119 Soft Capsules in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC).","status":"RECRUITING","sponsor":"Hinova Pharmaceuticals Inc.","startDate":"2019-04-12","conditions":"MCRPC","enrollment":417},{"nctId":"NCT03776968","phase":"PHASE1","title":"A Study Evaluating HC-1119 Single-Dose Pharmacokinetics and Effect of Food on Its Pharmacokinetics","status":"COMPLETED","sponsor":"Hinova Pharmaceuticals Inc.","startDate":"2017-10-24","conditions":"Metastatic Castration Resistant Prostate Cancer","enrollment":47},{"nctId":"NCT03850795","phase":"PHASE3","title":"HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)","status":"TERMINATED","sponsor":"Hinova Pharmaceuticals USA, Inc.","startDate":"2021-03-15","conditions":"Prostate Cancer Metastatic, Castration-resistant Prostate Cancer","enrollment":104},{"nctId":"NCT04986176","phase":"PHASE3","title":"HC-1119 Adjuvant Treatment for Hospitalized COVID-19 Patients","status":"UNKNOWN","sponsor":"Applied Biology, Inc.","startDate":"2022-04-15","conditions":"COVID-19 Respiratory Infection","enrollment":602},{"nctId":"NCT03778047","phase":"PHASE1","title":"A Study Evaluating Enzalutamide Pharmacokinetics and Pharmacodynamics, and Related Changes After Drug Switch","status":"COMPLETED","sponsor":"Hinova Pharmaceuticals Inc.","startDate":"2018-02-07","conditions":"Metastatic Castration Resistant Prostate Cancer","enrollment":10},{"nctId":"NCT03774056","phase":"PHASE1","title":"A Study Evaluating Tolerability, Pharmacokinetics, and Preliminary Efficacy of HC-1119 in Patients.","status":"COMPLETED","sponsor":"Hinova Pharmaceuticals Inc.","startDate":"2017-02-10","conditions":"Metastatic Castration Resistant Prostate Cancer","enrollment":43}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"HC-1119","genericName":"HC-1119","companyName":"Hinova Pharmaceuticals Inc.","companyId":"hinova-pharmaceuticals-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"HC-1119 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":3,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}